Header Logo

Connection

THOMAS WESTBROOK to Female

Back to Details
This is a "connection" page, showing publications THOMAS WESTBROOK has written about Female.
THOMAS WESTBROOK
Connection Strength
0.271
Female
  1. Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2025 Nov 03; 15(11):2326-2343.
    View in: PubMed
    Score: 0.037
  2. MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast Cancer. Cancer Discov. 2024 Sep 04; 14(9):1699-1716.
    View in: PubMed
    Score: 0.034
  3. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
    View in: PubMed
    Score: 0.022
  4. The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32.
    View in: PubMed
    Score: 0.017
  5. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53.
    View in: PubMed
    Score: 0.014
  6. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011 Mar 04; 144(5):703-18.
    View in: PubMed
    Score: 0.013
  7. An in vivo screen identifies NAT10 as a master regulator of brain metastasis. Sci Adv. 2025 Mar 28; 11(13):eads6021.
    View in: PubMed
    Score: 0.009
  8. Plasma protein-based and polygenic risk scores serve complementary roles in predicting inflammatory bowel disease. Pac Symp Biocomput. 2025; 30:522-534.
    View in: PubMed
    Score: 0.009
  9. IRE1a silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. 2024 Dec 12; 187(25):7248-7266.e34.
    View in: PubMed
    Score: 0.009
  10. Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. Elife. 2022 08 31; 11.
    View in: PubMed
    Score: 0.007
  11. Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Mol Cell. 2021 08 05; 81(15):3048-3064.e9.
    View in: PubMed
    Score: 0.007
  12. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. 2021 01 21; 184(2):384-403.e21.
    View in: PubMed
    Score: 0.007
  13. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. 2020 11 25; 183(5):1436-1456.e31.
    View in: PubMed
    Score: 0.007
  14. Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. Cell Rep. 2019 10 08; 29(2):249-257.e8.
    View in: PubMed
    Score: 0.006
  15. Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nat Cell Biol. 2019 09; 21(9):1113-1126.
    View in: PubMed
    Score: 0.006
  16. A Druggable Genome Screen Identifies Modifiers of a-Synuclein Levels via a Tiered Cross-Species Validation Approach. J Neurosci. 2018 10 24; 38(43):9286-9301.
    View in: PubMed
    Score: 0.006
  17. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. 2018 04; 556(7700):249-254.
    View in: PubMed
    Score: 0.005
  18. Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns. Cell. 2018 04 05; 173(2):499-514.e23.
    View in: PubMed
    Score: 0.005
  19. Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat Cell Biol. 2016 06; 18(6):632-44.
    View in: PubMed
    Score: 0.005
  20. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015 Sep 17; 525(7569):384-8.
    View in: PubMed
    Score: 0.005
  21. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene. 2016 Jan 28; 35(4):468-78.
    View in: PubMed
    Score: 0.004
  22. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015 Feb 09; 27(2):193-210.
    View in: PubMed
    Score: 0.004
  23. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
    View in: PubMed
    Score: 0.004
  24. Plk2 regulates mitotic spindle orientation and mammary gland development. Development. 2014 Apr; 141(7):1562-71.
    View in: PubMed
    Score: 0.004
  25. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014 Jan; 124(1):398-412.
    View in: PubMed
    Score: 0.004
  26. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature. 2013 Jun 20; 498(7454):325-331.
    View in: PubMed
    Score: 0.004
  27. A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife. 2013 Apr 30; 2:e00358.
    View in: PubMed
    Score: 0.004
  28. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.
    View in: PubMed
    Score: 0.004
  29. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3665-70.
    View in: PubMed
    Score: 0.003
  30. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009 May 29; 137(5):835-48.
    View in: PubMed
    Score: 0.003
  31. Biology of human papillomaviruses. Int J Exp Pathol. 2001 Feb; 82(1):15-33.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.